Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus.

Uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) represent more aggressive tumors than the more common endometroid cancers, exhibiting a propensity for distant metastasis. The aim of this study was to investigate the activity and safety of paclitaxel/carboplatin chemotherapy as the only adjuvant treatment in patients with surgically resected UPSC and UCCC.
Fifteen patients with Stage IB-IV UPSC or UCCC were treated with a mean of six courses of paclitaxel 175 mg/m3 plus carboplatin AUC 5 at three-week intervals, three to six weeks after undergoing surgery with curative intent. No patient had residual disease after surgery and none underwent pre- or post-chemotherapy irradiation.
With a median follow-up of 29.4 months, six patients (40%) relapsed and two (13%) died of disease. Mean time to recurrence was 16.9 months. Recurrence rate per Stage was 17% for Stage IB/C, 57% for Stage IIIA/C and 50% for Stage IV. Projected 5-year overall survival and progression-free survival was 79.7% and 55.7%, respectively. All relapses were abdominopelvic whereas in one case pelvic recurrence was accompanied by lung metastasis. The most frequent grade 3-4 toxicity was neutropenia.
Chemotherapy with paclitaxel plus carboplatin is feasible and possibly prevents distant metastasis when used as adjuvant in UPSC and UCCC.
AuthorsG T Bozas, A Bamias, E Kastritis, A Rodolakis, G Vlahos, C A Papadimitriou, S Markaki, M A Dimopoulos
JournalEuropean journal of gynaecological oncology (Eur J Gynaecol Oncol) Vol. 26 Issue 6 Pg. 627-31 ( 2005) ISSN: 0392-2936 [Print] Italy
PMID16398224 (Publication Type: Journal Article)
Chemical References
  • Carboplatin
  • Paclitaxel
  • Adenocarcinoma, Clear Cell (drug therapy, mortality)
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Carboplatin (administration & dosage, adverse effects)
  • Carcinoma, Papillary (drug therapy, mortality)
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Endometrial Neoplasms (drug therapy, mortality)
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local (epidemiology)
  • Neoplasm Staging
  • Paclitaxel (administration & dosage, adverse effects)
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: